This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Revimid, Revlemid, lenalidomide, CC-5013, CDC-501
IMiDs such as Revimid are novel, small-molecule, orally available analogs of thalidomide that are designed to be more potent and potentially have a better safety profile than the parent compound. Celgene's IMiDs have significantly greater immunological activity in in vitro studies. IMiDs were reported in the November 1, 2000 issue of BLOOD to enhance T-cell proliferation and interleukin (IL)-2 production. In the same report, IMiDs were also shown to be potent inhibitors of inflammatory cytokines that include TNF-alpha and IL-1beta while stimulating the anti-inflammatory cytokine IL-10.
Another major target may be the ligase protein, cereblon (CRBN; http://www.nature.com/leu/journal/v26/n11/full/leu2012119a.html).
Pink Sheet Revlimid FDA Reviewers
Pink Sheet Revlimid Clinical Development
Additional information available to subscribers only: